SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

DBV Technologies S.A.
Date: May 23, 2025 · CIK: 0001613780 · Accession: 0000000000-25-005519

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-287393

Date
May 23, 2025
Author
Division of
Form
UPLOAD
Company
DBV Technologies S.A.

Letter

Re: DBV Technologies S.A. Registration Statement on Form S-3 Filed May 19, 2025 File No. 333-287393 Dear Daniel Tass :

May 23, 2025

Daniel Tass Chief Executive Officer DBV Technologies S.A. 107 avenue de la R publique 92320 Ch tillon France

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tyler Howes at 202-551-3370 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Evan Leitner, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 May 23, 2025

Daniel Tass
Chief Executive Officer
DBV Technologies S.A.
107 avenue de la R publique
92320 Ch tillon France

 Re: DBV Technologies S.A.
 Registration Statement on Form S-3
 Filed May 19, 2025
 File No. 333-287393
Dear Daniel Tass :

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Tyler Howes at 202-551-3370 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Evan Leitner, Esq.
</TEXT>
</DOCUMENT>